Evidence map›Paper›PMID 32578713›Full record

ArticleRevista da Sociedade Brasileira de Medicina Tropical2020

Efficacy of the 7-chloro-4-(3-hydroxy-benzilidenehydrazo)quinoline derivative against infection caused by Leishmania amazonensis.

Luciana Maria Ribeiro Antinarelli, Marcus Vinicius Nora de Souza, Eduardo Antonio Ferraz Coelho, Wallace Pacienza Lima, Elaine Soares Coimbra

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Revista da Sociedade Brasileira de Medicina Tropical, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Luciana Maria Ribeiro AntinarelliUniversidade Federal de Juiz de Fora, Campus Universitário, Departamento de Parasitologia, Microbiologia e Imunologia, Juiz de Fora, MG, Brasil.
Marcus Vinicius Nora de SouzaFundação Oswaldo Cruz, Instituto de Tecnologia em Fármacos-FarManguinhos, Rio de Janeiro, RJ, Brasil.
Eduardo Antonio Ferraz CoelhoUniversidade Federal de Minas Gerais, Faculdade de Medicina, Programa de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Belo Horizonte, MG, Brasil.
Wallace Pacienza LimaUniversidade Federal do Rio de Janeiro, Instituto de Biofísica Carlos Chagas Filho, Laboratório de Imunofarmacologia, Rio de Janeiro, RJ, Brasil.
Elaine Soares CoimbraUniversidade Federal de Juiz de Fora, Campus Universitário, Departamento de Parasitologia, Microbiologia e Imunologia, Juiz de Fora, MG, Brasil.ORCID http://orcid.org/0000-0003-1005-278X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe drugs currently available for leishmaniasis treatment have major limitations.

methodsIn vitro and in vivo studies were performed to evaluate the effect of a quinoline derivative, Hydraqui (7-chloro-4-(3-hydroxy-benzilidenehydrazo)quinoline, against Leishmania amazonensis. In silico analyses of absorption, distribution, metabolism, excretion, and toxicity (ADMET) parameters were performed.

resultsHydraqui showed significant in vitro anti-amastigote activity. Also, Hydraqui-treated mice exhibited high efficacy in lesion size (48.3%) and parasitic load (93.8%) reduction, did not cause hepatic and renal toxicity, and showed appropriate ADMET properties.

conclusionsHydraqui presents a set of satisfactory criteria for its application as an antileishmanial agent.

Indexed as

AnimalsAntiprotozoal AgentsDisease Models, AnimalFemaleLeishmania mexicanaLeishmaniasis, CutaneousMiceMice, Inbred BALB CParasite LoadQuinolinesAntiprotozoal AgentsquinolineQuinolines

Identifiers

PMID32578713
PMCPMC7310358

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.